Advertisement admin, Author at Pharmaceutical Business review - Page 296 of 458
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

All articles by >>> https://t.me/+vCnQzRypNr0xZWRi#zgbasw <<< 56321668 >>> https://t.me/+vCnQzRypNr0xZWRi#zgbasw <<< 56321668

Xencor renegotiates XmAb5871 agreement with Amgen

XmAb5871 is a first-in-class monoclonal antibody containing Xencor’s proprietary immune inhibitor XmAb Fc domain that targets Fc?RIIb to inhibit B-cell function. XmAb5871 is currently in a Phase 1b/2a